The company plans to transition its DetermaIO test from research to clinical use and to launch a new research product for immunotherapy monitoring by the end of this year.
The firm said its test can be used to evaluate blood samples from people who present with suspicious growths in the breast, lung, prostate, colon, or brain.
PreludeDx's DCISionRT test is for women diagnosed with ductal carcinoma in situ or stage 0 breast cancer who are treated with breast-conserving surgery.
The firm expects to receive a CE mark later this year for its RT-qPCR breast cancer recurrence assay, which characterizes epithelial CTCs by detecting cytokeratin-19 expression.
The expert body now recognizes the test's ability to predict whether early-stage breast cancer patients will benefit from extended, adjuvant endocrine therapy.
